Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
Meta-analysis published in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2021)
Abstract
A variety of antithrombotic drugs are used during percutaneous coronary interventions (PCIs). We aimed to investigate the practicability of the use of bivalirudin and GPIs in patients receiving PCI. We searched 7 of 629 relevant records from PubMed, the Cochrane Library, EMBASE, and Web of Science for randomised controlled trials. There were no significant differences in the rates of major adverse cardiac events (MACE) between bivalirudin plus GPI and heparin (all P > .05). Bivalirudin plus planned GPI was similar to bivalirudin monotherapy in terms of the risk of MACE (risk ratio [RR] = 1.07; 95% confidence interval [CI] = .91 - 1.27; P = .55). Bivalirudin plus provisional GPI was associated with lower bleeding risk (RR = .57; 95% CI = .47 - .69; P < .01) compared to using heparin plus GPI. Compared to bivalirudin alone, bivalirudin plus planned GPI evidently increased bleeding risk (RR = 2.20; 95% CI = 1.73 - 2.79; P < .01). Patients receiving bivalirudin or heparin therapy had semblable efficacy endpoints, but those receiving bivalirudin had a significantly lower bleeding risk. For high-risk bleeding patients, bivalirudin plus provisional GPI can have a better antithrombotic effect than heparin, without increasing the bleeding risk.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
A variety of antithrombotic drugs are used during percutaneous coronary interventions (PCIs).
Por qué esto importa para la hirudoterapia
This meta-analysis of randomized controlled trials investigated the practicability of bivalirudin plus glycoprotein IIb/IIIa inhibitors (GPIs) compared with heparin or bivalirudin monotherapy in patients undergoing percutaneous coronary intervention. It found no significant difference in major adverse cardiac events between bivalirudin plus GPI and heparin, that bivalirudin plus provisional GPI was associated with lower bleeding risk than heparin plus GPI, and that bivalirudin plus planned GPI increased bleeding risk versus bivalirudin alone. The abstract contains no mention of hirudin, leeches, leech saliva, or any leech-derived component, and does not characterize bivalirudin as a hirudin analog. No defensible connection to hirudotherapy, the leech secretome, or ASH's domain can therefore be drawn from this source alone.
Citación
Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
Li S et al. · Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026